Baird Financial Group
PCRX icon

Baird Financial Group’s Pacira BioSciences PCRX Stock Holding History

Baird Financial Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,440
Closed -$245K – 1551
2019
Q1 		$245K Sell
6,440
-6,540
-50% -$255K ﹤0.01% 1197
2018
Q4 		$558K Buy
12,980
+6,949
+115% +$324K ﹤0.01% 954
2018
Q3 		$288K Buy
+6,031
New +$261K ﹤0.01% 1189
2018
Q1 		– Sell
-5,794
Closed -$264K – 1284
2017
Q4 		$264K Sell
5,794
-35
-0.6% -$1.39K ﹤0.01% 1156
2017
Q3 		$219K Buy
5,829
+474
+9% +$19.1K ﹤0.01% 1164
2017
Q2 		$255K Buy
5,355
+142
+3% +$6.59K ﹤0.01% 1127
2017
Q1 		$238K Buy
+5,213
New +$225K ﹤0.01% 1127

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baird Financial Group's PCRX Position: Q2 2019 in Review

Baird Financial Group sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 6,440 shares — an estimated $245K sold.

Baird Financial Group first reported a position in PCRX in Q1 2017 and held it in 7 quarters. The position peaked at $558K in Q4 2018. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

  • Baird Financial Group reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
  • Baird Financial Group sold 6,440 Pacira BioSciences shares in Q2 2019, an estimated $245K.
  • Baird Financial Group first reported a position in Pacira BioSciences in Q1 2017 and held it in 7 quarters.
  • Baird Financial Group's Pacira BioSciences position peaked at $558K in Q4 2018.
  • 218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Baird Financial Group's 13F filing for Q2 2019, filed 14 Aug 2019.